Two weight-loss
shots grew Lilly's
revenue 56% in
a year.
Mounjaro and Zepbound turned a 150-year-old drugmaker into the fastest grower in big pharma.
↓ scroll to read
✦ The bottom line
Lilly pulled in $19.8 billion in three months, up 56%. Two drugs built on the same molecule — Mounjaro (diabetes) and Zepbound (obesity) — did most of the work.
↓ the brief below
✦ Teach me
Money coming in
Every dollar Lilly earned in the quarter from selling medicines. The simplest measure of size. Not profit — the cost of making and selling the drugs comes out later.
Wall Street calls this
Revenue
Big, established drugmakers grow a few percent a year. *56%* means a genuine blockbuster — the kind that comes along once in a decade.
The headline number · latest quarter
$19.8
B
Money in for the three months ending March 2026 — up 56% from a year earlier, driven by a 65% jump in volume (units sold).
$19.8 billion is the size. But for Lilly, almost everything traces back to a single molecule — tirzepatide — sold under two names for two uses. The diabetes version is called Mounjaro. It's the bigger of the two, and it's growing at a rate big drugs almost never do. Here it is.
The bigger engine · Mounjaro (diabetes)
$8.7
B
Mounjaro revenue more than doubled — up 125% — with sales outside the U.S. nearly quadrupling as it reached new markets like China.
Same molecule, second act. When tirzepatide is sold for weight loss rather than diabetes, it's branded Zepbound. It launched more recently, so it's smaller — but it's already the most prescribed weight-loss medicine, and growing fast. Add the two together and you'll see how much of Lilly is really one drug.
The second act · Zepbound (obesity)
$4.2
B
Zepbound grew 80% to $4.2B. Together, Mounjaro and Zepbound are ~65% of all of Lilly's revenue — one molecule, two-thirds of the company.